Table 3 Associations between MICA/NKG2D polymorphisms and clinical data

From: MICA and NKG2D variants as risk factors in spondyloarthritis: a case–control study

  

n (%)

Clinical data n (OR (95% CI))

Uveitis

Psoriasis

IBD

SI

MICA 129 N = 162

  

N = 16

N = 44

N = 14

N = 110

Met

131 (80)

16

34

12

93

Val/Val

31 (20)

0 (∞ (0.97–∞))

10 (0.74 (0.29–1.93))

2 (1.45 (0.29–14.93))

17 (2 (0.82–4.28))

MICA A5.1 N = 161

  

N = 16

N = 44

N = 14

N = 109

abs

85 (53)

10

17

9

63

Hetero

9 (4)

0 (∞ (0.20–∞))

4 (0.45 (0.09–2.37))

0 (∞ (0.17–∞))

3 (4.5 (0.92–29.40))

Homo

67 (43)

6 (0.79 (0.37–4.27))

23 (0.55 (0.25–1.17))

5 (1.31 (0.37–5.23))

43 (1.37 (0.66–2.85))

NKC3 N = 160

  

N = 16

N = 43

N = 14

N = 109

C/C

27 (17)

4

5

2

19

G

133 (83)

12 (1.74 (0.37–6.45))

38 (0.57 (0.15–1.69))

12 (0.80 (0.08–3.91))

90 (1.13 (0.43–3.24))

NKC4 N = 160

  

N = 16

N = 43

N = 14

N = 109

T/T

8 (5)

1

2

2

5

C

153 (95)

15 (1.31 (0.02–11.42))

41 (0.91 (0.09–5.36))

12 (3.86 (0.34–24.95))

104 (0.43 (0.08–2.98))

  1. IBD inflammatory bowel disease, SI sacroiliac joint damage on X-ray or CT scan or magnetic resonance imaging, C cytosine, G guanine, Hetero heterozygous, Homo homozygous, Met methionine, T thymidine, Val valine
Back to article page